Neurofibromatosis Type 2 Management

Neurofibromatosis is a condition characterized by the growth of benign tumors along nerves in the body. The tumors can eventually grow large enough to compress surrounding nerves and other tissues, which causes various different symptoms depending on the tumor’s location. The main aim of treatment is to preserve function rather than to cure the condition.

Some of the approaches to managing neurofibromatosis type 2 are described below:

Watchful waiting

In cases of very slow growing or low-grade tumors, an approach called watchful waiting may be adopted. The patient is carefully monitored on a regular basis to assess tumor growth and check whether the condition is becoming symptomatic. The monitoring usually involves magnetic resonance imaging (MRI) scans, eye tests and hearing tests.

Early intervention with surgery

This approach is adopted by certain centres to eliminate the tumor early on, before symptoms have a chance to develop.

Vestibular schwannoma treatment

The tumors that develop along the nerves that control hearing and balance are called vestibular schwannomas. If the tumor is small, it may be removed without causing any damage to the hearing but if a tumor has grown, surgery can be complicated if nerves that affect the facial movement, balance and hearing are involved. An alternative to conventional surgery is radiosurgery which may be used to reduce the size of the tumor instead.

Hearing preservation

Several techniques can be used to preserve or improve the hearing including surgical hearing implants and speech and language therapy, for example. In cases of complete hearing loss due to damaged cochlear nerves, auditory brain stem implants may be used.


Some medications that may have beneficial effects in neurofibromatosis type 2 include lapatinib, a tyrosine kinase that inhibitis EGFR receptors; an immunosuppressant called everolimus and a monoclonal antibody called bevacizumab that inhibits vascular endothelial growth factor (VEGF) and therefore tumour angiogenesis (new blood vessel growth within tumors).

Further Reading

Last Updated: Dec 31, 2022

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2022, December 31). Neurofibromatosis Type 2 Management. News-Medical. Retrieved on June 02, 2023 from

  • MLA

    Mandal, Ananya. "Neurofibromatosis Type 2 Management". News-Medical. 02 June 2023. <>.

  • Chicago

    Mandal, Ananya. "Neurofibromatosis Type 2 Management". News-Medical. (accessed June 02, 2023).

  • Harvard

    Mandal, Ananya. 2022. Neurofibromatosis Type 2 Management. News-Medical, viewed 02 June 2023,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment